MedCity News February 9, 2024
Krish Ramadurai

The new era of full-stack compute-enabled bio companies will drive incredible advances in human health.

The first biotech revolution began 50 years ago when molecular biologists used DNA engineering to introduce a foreign genetic sequence into a bacteria and successfully produce a protein not encoded by the host genome. This revolutionary moment enabled a new era of scientific research that has radically advanced our understanding of how cells function in health and disease. It also opened the door to wholly new classes of therapies (recombinant proteins, monoclonal antibodies, targeted small molecules, gene and cell therapies, and gene editing) that have improved health outcomes for millions of patients.

Despite the transformative power of the first biotech revolution, traditional biopharmaceutical drug development...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
Drugmakers counter HHS' first offers in Medicare price talks
Pfizer stops buildout of $350M Seagen plant, leaving 120 workers' roles in question
ARPA-H behind on duplicative research efforts, GAO says
Science Continues To Outpace Commercialization Of Cell And Gene Therapies
Opinion: Missing data is making it difficult for the pharmaceutical industry to help LGBTQ+ people

Share This Article